MYRIAD GENETICS INC's ticker is MYGN and the CUSIP is 62855J104. A total of 235 filers reported holding MYRIAD GENETICS INC in Q3 2015. The put-call ratio across all filers is 0.99 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2016 | $15,256,000 | -18.1% | 498,546 | +0.2% | 0.50% | -23.0% |
| Q1 2016 | $18,632,000 | -4.0% | 497,771 | +10.7% | 0.65% | -5.1% |
| Q4 2015 | $19,406,000 | +14.0% | 449,621 | -1.0% | 0.69% | +14.1% |
| Q3 2015 | $17,024,000 | -8.2% | 454,211 | -16.8% | 0.60% | +9.7% |
| Q2 2015 | $18,547,000 | -4.2% | 545,647 | -0.3% | 0.55% | -5.4% |
| Q1 2015 | $19,370,000 | +34.4% | 547,182 | +29.3% | 0.58% | +34.7% |
| Q4 2014 | $14,414,000 | -8.3% | 423,192 | +3.8% | 0.43% | -9.3% |
| Q3 2014 | $15,718,000 | -1.0% | 407,523 | -0.1% | 0.47% | -2.9% |
| Q2 2014 | $15,877,000 | +13.9% | 407,951 | +0.1% | 0.49% | +14.8% |
| Q1 2014 | $13,934,000 | +69.6% | 407,556 | +4.1% | 0.42% | +54.0% |
| Q4 2013 | $8,214,000 | -25.4% | 391,516 | -16.4% | 0.28% | -27.7% |
| Q3 2013 | $11,011,000 | +35.2% | 468,535 | +54.6% | 0.38% | -21.4% |
| Q2 2013 | $8,142,000 | – | 303,021 | – | 0.49% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 2,750,000 | $75,900,000 | 2.61% |
| PFM Health Sciences, LP | 2,025,681 | $55,909,000 | 1.90% |
| Tieton Capital Management, LLC | 118,456 | $3,269,000 | 1.83% |
| Altium Capital Management LP | 190,000 | $5,244,000 | 1.45% |
| DISCIPLINED GROWTH INVESTORS INC /MN | 1,846,490 | $50,963,000 | 1.03% |
| EARNEST PARTNERS LLC | 6,316,365 | $174,332,000 | 1.01% |
| Glenview Capital Management | 1,679,747 | $46,361,000 | 0.99% |
| Zebra Capital Management LLC | 14,209 | $392,000 | 0.63% |
| AIMZ Investment Advisors, LLC | 44,185 | $1,220,000 | 0.48% |
| Phocas Financial Corp. | 132,101 | $3,646,000 | 0.46% |